Biotech Values

[poorgradstudent]

Stan Hazen at the Cleveland Clinic has really been one of the researchers on the forefront of this field. His work on myeloperoxidase hasn't escaped dcgn's attention.

Decode is a special case in that they really cherry pick their trial participants. Their strength of being able to use the Icelandic population as a database may also become a weakness when they're forced to pursue their large clinical trials in North America with a more heterogenous population.

I shorted dcgn this morning and just covered. The PR was really not as significant as the price pop made it out to be... the drug works as an inhibitor, as designed. The heavy lifting has yet to come.